文献速递抗栓抗凝管理药物不良反应与药物警戒

BMS-962212(小分子因子XIa抑制剂)在健康日本与非日本受试者中的首次人体安全性、药代动力学与药效学研究

First-in-human study to assess the safety, pharmacokinetics and pharmacodynamics of BMS-962212, a direct, reversible, small molecule factor XIa inhibitor in non-Japanese and Japanese healthy subjects.
PubMed 文献 · Br J Clin Pharmacol · 2018-03-05

本研究为随机、安慰剂对照、双盲、序贯递增剂量首次人体试验,评估BMS-962212在健康日本与非日本受试者中的安全性、药代动力学与药效学。结果显示该药耐受良好,无出血迹象,不良事件轻微,呈剂量比例性暴露,aPTT与FXI:C呈暴露依赖性变化,日本与非日本受试者间无差异。

要点

  • BMS-962212在健康受试者中耐受良好,无出血迹象,不良事件为轻度。
  • A部分和B部分均显示剂量比例性药代动力学,半衰期分别为2.04–4.94 h和6.22–8.65 h。
  • 20 mg h-1时aPTT和FXI:C最大平均变化分别为92%和90%,日本与非日本受试者间无差异。

核心结论

  • BMS-962212在健康日本与非日本受试者中耐受良好,药代动力学和药效学特性适合作为急性抗血栓药物进一步研究。

研究设计与样本

  • 随机、安慰剂对照、双盲、序贯递增剂量首次人体研究,A部分为2小时静脉输注,B部分为5天静脉输注。
  • A部分使用1.5、4、10和25 mg h-1四个剂量,BMS-962212与安慰剂按6:2比例分配。
  • B部分使用1、3、9和20 mg h-1四个剂量,每个剂量纳入日本受试者(活性药n=4,安慰剂n=1)和非日本受试者(活性药n=4,安慰剂n=1)。

主要发现

  • BMS-962212耐受良好,无出血迹象,不良事件为轻度。
  • A部分和B部分均显示剂量比例性药代动力学。
  • A部分平均半衰期为2.04至4.94小时,B部分为6.22至8.65小时。
  • 药效学参数aPTT和FXI:C呈暴露依赖性变化,B部分20 mg h-1时最大平均aPTT和FXI:C较基线变化分别为92%和90%。
  • 日本与非日本受试者间体重校正稳态浓度、aPTT或FXI:C无差异(P > 0.05)。

临床怎么用

  • 该首次人体研究提示BMS-962212在健康受试者中安全性良好,支持其作为急性抗血栓药物的后续临床开发。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: The aims of the present study were to assess the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of BMS-962212, a first-in-class factor XIa inhibitor, in Japanese and non-Japanese healthy subjects. METHODS: This was a randomized, placebo-controlled, double-blind, sequential, ascending-dose study of 2-h (part A) and 5-day (part B) intravenous (IV) infusions of BMS-962212. Part A used four doses (1.5, 4, 10 and 25 mg h-1 ) of BMS-962212 or placebo in a 6:2 ratio per dose. Part B used four doses (1, 3, 9 and 20 mg h-1 ) enrolling Japanese (n = 4 active, n = 1 placebo) and non-Japanese (n = 4 active, n = 1 placebo) subjects per dose. The PK, PD, safety and tolerability were assessed throughout the study. RESULTS: BMS-962212 was well tolerated; there were no signs of bleeding, and adverse events were mild. In parts A and B, BMS-962212 demonstrated dose proportionality. The mean half-life in parts A and B ranged from 2.04 to 4.94 h and 6.22 to 8.65 h, respectively. Exposure-dependent changes were observed in the PD parameters, activated partial thromboplastin time (aPTT) and factor XI clotting activity (FXI:C). The maximum mean aPTT and FXI:C change from baseline at 20 mg h-1 in part B was 92% and 90%, respectively. No difference was observed in weight-corrected steady-state concentrations, aPTT or FXI:C between Japanese and non-Japanese subjects (P > 0.05). CONCLUSION: BMS-962212 has tolerability, PK and PD properties suitable for investigational use as an acute antithrombotic agent in Japanese or non-Japanese subjects.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Perera V, Luettgen JM, Wang Z, et al. First-in-human study to assess the safety, pharmacokinetics and pharmacodynamics of BMS-962212, a direct, reversible, small molecule factor XIa inhibitor in non-Japanese and Japanese healthy subjects. Br J Clin Pharmacol. 2018. PMID: 29346838. doi:10.1111/bcp.13520

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。